Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs

Sleep Research Online

Volumn 3, Issue 1, 2000, Pages 23-28

  John, Joshi ^b   Wu, Ming Fung ^b   Siegel, Jerome M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; CATAPLEXY; CIRCADIAN RHYTHM; DISEASE MODEL; DOG; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR ACTIVITY; NARCOLEPSY; PATHOPHYSIOLOGY; SLEEP; SLEEP STAGE; TREATMENT OUTCOME; WAKEFULNESS;

ANIMALS; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CATAPLEXY; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; FEMALE; INJECTIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MOTOR ACTIVITY; NARCOLEPSY; NEUROPEPTIDES; SLEEP; SLEEP STAGES; TREATMENT OUTCOME; WAKEFULNESS;

EID: 0034570309     PISSN: 1096214X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aldrich MS. Narcolepsy. Neurology 1992; 42(suppl 6): 34-43.
2. Aldrich MS. Diagnostic aspects of narcolepsy Neurology 1998; 1950: S2-7.
3. Baker TL, Dement WC. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In: McGinty DJ, Drucker-Colin R, Morrison A, Parmeggiani P, eds. Brain mechanisms of sleep. New York: Raven Press, 1985, pp. 199-233.
4. Bliwise D. Dementia. In: Kryger MH, Roth T, Dement WC, eds. The Principles and Practice of Sleep Medicine, Vol 2. Philadelphia: WB. Saunders, 1994, pp. 790-800.
5. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
6. Chen C-T, Harrison TA, Dun SL, Hwang LL, Dun NJ, Chang J-K. Intracisternal administration of orexins increased blood pressure and heart rate in urethane anesthetized rats. Soc Neurosci Abst 1999; 25: 12
7. Dube MG, Kalra SP, Kalra PS. Food intake elicited by central administration of orexin/hypocretins: identification of hypothalamic sites of action. Brain Res 1999; 842: 473-7.
8. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DNC, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999; 96: 10911-16.
9. Horvath TL, Peyron C, Dialno S, Ivanov A, Aston-Jones G, Kilduff TS, van den Pol AN. Hypocretin (Orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 1999; 415: 145-59.
10. Ida T, Nakahara K, Katayama T, Murakami N, Nakazato M. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res 1999; 821: 526-9.
11. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999; 289: 219-23.
12. Kirchgessner AL, Liu M. Orexin synthesis and response in the gut. Neuron 1999; 24: 941-51.
13. Kiyashchenko LI, Mileykovskiy BY, Siegel JM. Hypocretin microinjections in the vicinity of locus coeruleus change muscle tone in decerebrate rats. Sleep 2000; 23(2): 811.
14. Lai YY, Siegel JM. Medullary regions mediating atonia. J Neurosci 1988; 8: 4790-6.
15. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X-Y, Qiu X-H, de Jong PJ, Nishino S, Mignot E. The REM sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell 1999; 98: 365-76.
16. Lucas EA, Foutz AS, Dement WC, Mitler MM. Sleep cycle organization in narcoleptic and normal dogs. Physiol Behav 1979; 23: 737-43.
17. Mitler MM, Dement WC. Sleep studies on canine narcolepsy: pattern and cycle comparisons between affected and normal dogs. Electroencephalogr Clin Neurophysiol 1977; 43: 691-9.
18. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. The Lancet 2000; 355: 39-40.
19. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexin and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85
20. Siegel JM, Nienhuis R, Fahringer HM, Paul R, Shiromani P, Dement WC, Mignot E, Chiu C. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991; 252: 1315-18.
21. Siegel JM. Narcolepsy: A key role for hypocretins (Orexins). Cell 1999; 98: 409-12.
22. Takahashi N, Okumura T, Yamada H, Kohgo Y. Stimulation of gastric acid secretion by centrally administered orexin-Ain conscious rats. Biochem Biophys Res Commun 1999; 254: 623-7.
23. Wu M-F, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999; 91: 1389-99.
24. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999; 849: 248-52.